Colorectal cancer
Conditions
Interventions
Trial group:Fumarate Tegideridine injection: loading dose 1.0 mg + 0.05 mg, followed by administration via PCA pump, concentration 0.02 mg/mL, single effective push volume 2.5 mL, minimum interval bet
Control group:Morphine injection: loading dose 2 mg + 1 mg, followed by administration via PCA pump, concentration 0.4 mg/mL, single effective push volume 2.5 mL, minimum interval between two effectiv
Sponsors
Quzhou People Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Ages =18; 2. Patients undergoing laparoscopic colorectal cancer resection; 3. ASA I - II; 4. Body Mass Index (BMI) =18 kg/m^2 or =28 kg/m^2; 5. The patient voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. History of difficult airway; 2. Neurological disorders (e.g., depression) or epilepsy; 3. SpO211.1 mmol/L); 5. Severe hepatic impairment (Child-Pugh C); 6. Allergy or contraindication to opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), or antiemetics; 7. Patients currently participating in or planning to participate in any interventional clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resting Sum of Pain Intensity Difference in 48hours; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative hospital stay;Record treatment-related adverse events (e.g., nausea, vomiting, respiratory depression, dizziness, and bradycardia);Record postoperative recovery (time to first flatus) for two groups of patients;Time of first getting out of bed;Cumulative dose and the proportion of subjects who did not receive rescue analgesia;Sum of pain intensity during exercise (aSPID48) (the degree of pain during an exercise state, such as during coughing);Time of first administration of rescue analgesic; | — |
Countries
China
Contacts
Public ContactZheng Lihua
Quzhou People Hospital
Outcome results
None listed